


Azenta Life Sciences

UBS Genomics 2.0 and MedTech Innovations Summit August 11, 2022



Safe Harbor Statement




"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from those projected. Further discussions of risk factors are available in the Company's most recent SEC filings, including the annual report on Form 10-K for the fiscal year ended September 30, 2021 and any subsequent quarterly reports on Form 10-Q. The Company assumes no obligation to update the information in this presentation.

Regulation G

This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Azenta business and its operational performance. These measures should always be considered in conjunction with the appropriate GAAP measure. Reconciliations of all non-GAAP amounts to the relevant GAAP amount are provided as a separate presentation on the Company's website. All financial projections throughout this presentation, other than ROIC, exclude amortization of intangibles, restructuring expense and other special charges.

Azenta Life Sciences at a Glance






Data shown is based on continuing operations; segment chart is LTM 6/30/2022

*LTM organic growth removes the impacts of FX and M&A; ex-COVID removes the company's estimate of COVID-related revenue

**Estimated net cash after Barkey acquisition completed 7/1/22 and completion of pending acquisition of B Medical Systems expected in October 2022


© 2022 Azenta, Inc. • Proprietary Information

Established Strong Foundation – Zero to \$500M in 10 years 🖉 AZENTA





The Azenta Portfolio Is a Key Enabler Across the Sample Solutions and Management Value Chain



Critical CGT Customer Needs Solved By Unique Azenta Offerings



Reliable management of patient samples and therapies at ultracold temperatures






Azenta Solution:

- Enables critical temperature and location tracking
- ✓ Automated storage at ultracold and cryogenic temperatures
- ✓ On-Site (Biostore) and Offsite solutions (Azenta's Global Biorepository)

Reproducible AAV sequencing and synthesis for R&D



Azenta Solution:

- Proprietary methods and reagents
- ✓ AAV-ITR sanger sequencing
- ✓ AAV NGS sequencing
- \checkmark AAV plasmid synthesis

Critical controlled-rate thawing of cryopreserved therapies






Azenta Solution :

- Controlled-rate thawing devices for cryopreserved raw materials and patient therapies
- ✓ Providing maximum viability
- Only device of its kind FDA approved for use in patient care

Diverse Revenue Profile Aligned for Higher Growth








A Global Leader in Vaccine Cold Chain and Temperature-Controlled Transport Solutions






CY2021 REVENUE BY BUSINESS LINE



Vaccine Cold Chain

- Medical Refridgeration
- Blood Management and Other

CY2021 REVENUE BY GEOGRAPHY



MORE THAN

500,000

SYSTEMS INSTALLED IN MORE THAN

150

COUNTRIES

MORE THAN

OF GLOBAL EXPERIENCE

YEARS

Pending Acquisition of B Medical Systems



Key Transaction Highlights



- Acquiring B Medical for approximately €410M cash plus up to an additional €50M cash earnout
- Financed through cash on hand



OCT

2022

• €109 million LTM 6/30/2022 revenue, which includes €19 million COVID-related revenue

- Accretive to FY23 non-GAAP earnings and accretive to FY24 GAAP earnings
 Exposted to close in October 2022
- Expected to close in October 2022



Proven Track Record in Successful M&A: 10 Years, >10 Transactions, ~\$1B Capital with ROIC Focus



Acquisition Focus

- Strategic fit to add value
- ROIC > WACC in 5-7 years
 - High growth
 - Profit leverage

AZENTA

LIFE SCIENCES

Strategy Going Forward



Extend leadership in core markets

Invest for organic growth and strategic M&A


Brive margin expansion

4 Utilize balanced and disciplined capital deployment with ROIC focus



Disciplined Approach to Capital Deployment






Prioritizing cash for M&A opportunities and organic investment

Note: Suzhou, China building project adds 3-4 points to CAPEX % of revenue in 2020 -22 *Estimated net cash after Barkey acquisition completed 7/1/22 and completion of pending acquisition of B Medical Systems expected in October 2022 © 2022 Azenta, Inc. • Proprietary Information

Track Record of Organic Growth Supplemented by M&A





Guidance As Provided August 9, 2022



Continuing Operations

\$M except EPS	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	August Guidance Q4'22 **
Total Revenue	\$129M	\$137M	\$140M	\$146M	\$133M	\$131 - \$141M
Adjusted EBITDA*	\$18.7	\$21.2	\$19.8M	\$19.4M	\$13.8M	\$8 - \$14M
EPS*	\$0.10	\$0.12	\$0.12	\$0.12	\$0.12	\$0.04 - \$0.12

* Non-GAAP financial measures

** Guidance is as of August 9, 2022 and is being provided for historical informational purposes and is not to be viewed as reissued or updated information in this presentation

Differentiated End-to-End Sample Management Portfolio

\$650M+ revenue company following the pending acquisition of B Medical Systems with growth and margin expansion opportunities

Strong balance sheet with an experienced and capable team

3

1

2


Global platform that can support more capabilities and customers

Strong value proposition with >\$2B in cash to deploy following the pending acquisition of B Medical Systems





Appendix



Portfolio Offering Examples







GAAP to Non-GAAP Reconciliation

Continuing Operations – Total Azenta

\$ millions, except EPS	Q3 FY21	Q4 FY21	Q1 FY22	Q2 FY22	Q3 FY22
Revenue	129.1	136.9	139.7	145.5	132.7
GAAP gross profit	62.4	66.1	67.0	70.8	59.6
Gross profit margin	48.4%	48.3%	48.0%	48.7%	44.9%
Amortization expense	2.2	1.9	1.8	1.8	1.8
Tariff adjustment	-	-	-	(0.5)	0.0
Other special charges	(0.1)	-	-	-	-
Non-GAAP gross profit	64.5	68.0	68.8	72.2	61.4
Non-GAAP gross profit margin	50.0%	49.7%	49.3%	49.6%	46.3%
GAAP Research and development	(5.5)	(6.6)	(6.5)	(6.9)	(6.5)
GAAP Selling, general and administrative	(57.8)	(80.5)	(60.7)	(68.5)	(58.1)
Merger and acquisition costs	2.5	8.4	3.7	5.6	1.7
Amortization expense	7.4	7.6	6.3	6.0	5.7
Other special charges	-	14.2	0.6	1.3	0.3
Non-GAAP Selling, general and administrative	(47.9)	(50.2)	(50.1)	(55.6)	(50.4)
Restructuring charges	0.0	(0.3)	(0.2)	(0.1)	(0.0)
GAAP operating profit (loss)	(0.9)	(21.2)	(0.3)	(4.7)	(5.1)
Operating profit margin	(0.7%)	(15.5%)	(0.2%)	(3.2%)	(3.8%)
Non-GAAP operating profit	11.1	11.2	12.2	9.7	4.4
Non-GAAP operating profit margin	8.6%	8.2%	8.8%	6.7%	3.4%
GAAP net income (loss)	(1.8)	(22.4)	2.9	(1.8)	(7.0)
Merger and acquisition costs	2.5	8.4	3.7	5.6	1.7
Amortization expense	9.6	9.5	8.0	7.9	7.6
Restructuring charges	(0.0)	0.3	0.2	0.1	0.0
Other special charges	(0.1)	14.2	0.6	1.3	0.3
Tariff adjustment	-	-	-	(0.5)	0.0
Loss on extinguishment of debt	-	-	-	0.6	-
Tax related adjustments	0.1	(10.2)	(4.2)	(0.9)	8.4
Tax effect of adjustments	(2.6)	8.9	(2.3)	(3.6)	(2.1)
Non-GAAP net income	7.7	8.8	8.9	8.7	8.8
Diluted earnings per share	(0.02)	(0.30)	0.04	(0.02)	(0.09)
Non-GAAP diluted earnings per share	0.10	0.12	0.12	0.12	0.12



Net Income to Adjusted EBITDA Reconciliation

Continuing Operations – Total Azenta

\$ millions	Q3 FY21	Q4 FY21	Q1 FY22	Q2 FY22	Q3 FY22
Net income	39.2	21.8	43.3	2,119.9	(9.6)
Income (Loss) from discontinued operations, net of tax	(41.0)	(44.2)	(40.5)	(2,121.7)	2.6
Net income (Loss) from continuing operations	(1.8)	(22.4)	2.9	(1.8)	(7.0)
Adjustments:					
Interest income	(0.4)	(0.1)	(0.0)	(3.1)	(6.8)
Interest expense	0.5	0.6	0.5	1.6	2.1
Income tax provision	(0.8)	(15.5)	(4.7)	(3.2)	7.3
Depreciation	4.9	5.1	5.2	5.3	5.3
Amortization of intangible assets	9.6	9.5	8.0	7.9	7.6
Loss on extinguishment of debt	-	-		0.6	-
EBITDA - from Continuing Operations	11.9	(22.9)	11.9	7.3	8.4
Adjustments:					
Stock-based compensation	4.3	5.1	3.5	5.5	3.5
Rebranding and transformation	-	0.8	0.6	1.3	0.3
Tax indemnification reserve release	-	16.0	-	-	-
Impairment of trademark	-	13.4	-	-	-
Tariff adjustment	(0.1)	-	-	(0.5)	-
Restructuring charges	(0.0)	0.3	0.2	0.1	0.0
Merger and acquisition costs / Other	2.5	8.4	3.7	5.6	1.7
Adjusted EBITDA - from Continuing Operations	18.7	21.2	19.8	19.4	13.8
Adjusted EBITDA margin	14.5%	15.5%	14.2%	13.3%	10.4%